Camurus Submits New Drug Application to the US FDA for Oclaiz for Treatment of Acromegaly

Lund, Sweden— 21 December 2023— Camurus (NASDAQ STO: CAMX) today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for OclaizTM (CAM2029), the company’s investigational,...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news